ClinicalTrials.gg
RecruitingNCT06999057Updated May 1, 2026

Quadriceps Motor Unit Adaptation to Simulated Knee Injury

An Early Phase 1 interventional study of Joint Effusion via 60 mL Sterile Saline and Intra-articular Lidocaine in Muscle Inhibition and Knee Injury Simulation, sponsored by University of Central Florida. Recruiting at 1 site in United States. Open to participants aged 18 Years to 30 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-05-01.

Sponsored by University of Central Florida · Early Phase 1, Interventional, and Basic science

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Early Phase 1
Study type
Interventional
Enrollment
45
Allocation
Randomized
Ages
18 Years to 30 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 94 studies in Knee Injuries with a site in United States — 16 open to participants now, 24 under way, 1 of them phase 3. Knee Injuries · United States.

Planned enrollment
36th of 75
45 · median 40
Started
2026
with 2 others
Phase 1
2 of 94
1 open now
Primary completion
2027-08
later than 14 of 23 live
Registered
90th of 94
by date

Among the 94 studies in Knee Injuries with a site in United States, this one is the 36th largest by planned enrollment of the 75 interventional ones that give a count, is one of 3 that started in 2026, is one of 2 in phase 1, reaches primary completion later than 14 of the 23 other live ones, and was the 90th registered.

Knee Injuries

267 studies on the registry are indexed under Knee Injuries; 59 are open to participants now.

Browse Knee Injuries studies →

Open to participants now

16 of the 94 studies in Knee Injuries with a site in United States are open now. Recruiting first, the newest first:

10 more — sign in →

All 16 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 42 Knee Injuries studies recruiting now, 12 (29%) set no upper age limit and 27 (64%) stop at 75 or younger; 12 take children under 18; 9 take healthy volunteers.

This study: 18 Years to 30 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 94 studies in Knee Injuries with a site in United States, or all of them as a file.
02

Study summary

This study investigates how simulated knee injury-via artificial joint effusion or deafferentation-affects quadriceps motor unit behavior in healthy young adults. Participants will complete neuromuscular testing during a single 2-hour lab session. This research seeks to improve understanding of muscle inhibition and inform interventions after real-world knee trauma.

Read the detailed description

Using a controlled laboratory model, the investigators will simulate knee injury through two methods: (1) intra-articular saline injection to induce effusion, and (2) intra-articular lidocaine injection to induce sensory deafferentation. Healthy participants aged 18-30 will undergo surface and decomposition EMG, isometric strength testing, and reflex measurements before and after the intervention. The primary outcome is motor unit recruitment characteristics, with secondary outcomes including quadriceps inhibition (Hoffmann reflex) and isometric peak torque. The findings will inform future neuromodulatory approaches in rehabilitation.

03

Conditions studied

  • Muscle Inhibition
  • Knee Injury Simulation

Browse trials for

Keywords

  • Quadriceps
  • Electromyography
  • Motor Unit
  • Knee Effusion
  • Lidocaine
  • Deafferentation
  • Neuromuscular Adaptation
  • Muscle Strength
04

Who can participate

Ages eligible
18 Years to 30 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age 18-30 years
  2. Physically active (Tegner ≥ 5)
  3. No prior lower-limb surgery or major injury

Exclusion criteria

Exclusion Criteria:

  1. Lower limb surgery or significant injury in past 2 years
  2. Cardiopulmonary, neurological, or psychiatric disorders
  3. Needle/electrical stimulation anxiety
  4. Medications affecting neuromuscular or psychological function
  5. Pregnancy
  6. Allergic to lidocaine
  7. Inability to elicit Hoffmann reflex
05

Study design

Phase
Early Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
45 participants (estimated)

Study arms

  • Experimental
    Effusion Group

    60 mL sterile saline injected into knee

    Device: Joint Effusion via 60 mL Sterile Saline

  • Active comparator
    Deafferentation Group

    Lidocaine (single intra-articular dose)

    Drug: Intra-articular Lidocaine

  • Sham comparator
    Control Group

    Sham procedure with fake needle

    Other: Sham injection

Interventions

  • DeviceJoint Effusion via 60 mL Sterile Saline

    Injection of sterile saline into the knee joint to simulate joint swelling and induce quadriceps inhibition.

  • DrugIntra-articular Lidocaine

    Injection of 7 mL lidocaine into the knee joint to simulate deafferentation by temporarily blocking sensory input.

  • OtherSham injection

    Simulated knee injection using a stage needle without skin penetration, used to blind participants and serve as control.

06

What researchers measure

Primary outcomes

  1. Motor Unit Recruitment (amplitude relative to recruitment threshold)

    Measured via surface EMG decomposition

    Time frame: Baseline, 0, 30, and 60 minutes post-intervention

  2. Motor Unit Recruitment (firing rate relative to recruitment threshold)

    Measured via surface EMG decomposition

    Time frame: Baseline, 0, 30, and 60 minutes post-intervention

Secondary outcomes

  1. Quadriceps Inhibition (Hoffmann Reflex)

    Measured with femoral nerve stimulation

    Time frame: Baseline, 0 and 60 minutes post-intervention

  2. Isometric Peak Torque (Quadriceps Strength)

    Measured with isokinetic dynamometer (Biodex)

    Time frame: Baseline and 60 minutes post-intervention

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — De-identified individual participant data (IPD) related to primary and secondary outcomes, including motor unit recruitment characteristics, quadriceps strength, and Hoffmann reflex measurements, will be shared with qualified researchers upon reasonable request.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form

Time frame: The IPD and supporting documentation will be available beginning 6 months after publication of the primary manuscript. Data will remain available for 5 years following that date.

Access criteria: Qualified researchers with appropriate data use agreements in place may request access. Requests should be submitted to the Principal Investigator via email and will be reviewed by the study team. Data will be shared via secure file transfer protocols.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Aug 2026; primary completion for Aug 2027, 12 months later.

How these figures are worked out, and which studies are left out of them.

Registered
May 20, 2025
First posted
May 31, 2025
StartEst.
Aug 1, 2026
Primary completionEst.
Aug 1, 2027
CompletionEst.
Aug 1, 2027
Last update
May 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 1, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06999057
Responsible party
Grant Norte (Associate Professor, University of Central Florida) — Principal investigator
First posted
May 31, 2025
Start date
Aug 1, 2026 (estimated)
Primary completion
Aug 1, 2027 (estimated)
Completion
Aug 1, 2027 (estimated)
Last update
May 1, 2026

Study contacts

Grant Norte, Ph.D.
Contact
Grant.Norte@ucf.edu
407-823-3188
Meredith Chaput, Ph.D.
Contact
Meredith.Chaput@ucf.edu

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion